TriangleBMS-986504 + Pemetrexed (NCT07594626)
BMS-986504 + Pemetrexed trial for Metastatic MTAP-Deleted Solid Tumors (NCT07594626). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic solid tumors that have an MTAP deletion, such as pancreatic, biliary, esophageal and colon cancers.
The idea: combine BMS-986504, a PRMT5 inhibitor taken by mouth daily, with the chemotherapy pemetrexed, given by vein, in 21 day cycles. MTAP deletion means the MTAP gene is missing.
This phase 1 and 2 study plans 72 patients and first looks at dose limiting side effects. At Northwestern University in Chicago, Devalingam Mahalingam leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.